# Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

> **NCT06228066** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 45 (estimated)

## Conditions studied

- Small Cell Carcinoma of the Bladder
- High Grade Neuroendocrine Tumors of the Urinary Tract

## Interventions

- **DRUG:** Lurbinectedin
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT06228066
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-13
- **Primary completion:** 2027-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06228066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06228066, "Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06228066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*